# US 2012/0232085 A1 · 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232085 A1
- Document ID: US20120232085A1
- Status: Published application
- Kind: A1
- Application number: 13/482,626
- Filed: 2012-05-29
- Published: 2012-09-13
- Earliest claimed: 2008-03-28
- Assignees: Nerviano Medical Sciences S.R.L.
- Inventors: Giovanni CERVI; Matteo D'ANELLO; Gianluca Mariano Enrico PAPEO; Barbara SALOM
- Web page: https://patentgrep.com/patent/US20120232085A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds which are 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

## Claims

### Claim 1

A method for treating a disease caused by and/or associated with a dysregulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I)
wherein
R is selected from the group consisting of —Ra, —CORa, —CONRaRb, —SO2Ra and —COORa, and
R1 is a group —NRcRd or —ORc ,
wherein Ra, Rb, Rc and Rd, the same or different, are each independently hydrogen or a group optionally further substituted, selected from straight or branched C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, C3-C6 cycloalkyl or cycloalkyl C1-C6 alkyl, heterocyclyl or heterocyclyl C1-C6 alkyl, aryl or aryl C1-C6 alkyl, heteroaryl or heteroaryl C1-C6 alkyl or, taken together with the nitrogen atom to which they are bonded, either Ra and Rb as well as Rc and Rd may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease caused by and/or associated with a dysregulated protein kinase activity is selected from the group consisting cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the cancer is selected from the group consisting of carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukaemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including mesothelioma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.

### Claim 4 (depends on 1)

An in vitro method for inhibiting protein kinase activity which comprises contacting the kinase with an effective amount of a compound of formula (I) as defined in claim 1.

### Claim 5

A compound of formula (I)
wherein
R is selected from the group consisting of —Ra, —CORa, —CONRaRb, —SO2Ra and —COORa, and
R1 is a group —NRcRd or —ORc,
wherein Ra, Rb, Rc and Rd, the same or different, are each independently hydrogen or a group optionally further substituted, selected from straight or branched C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, C3-C6 cycloalkyl or cycloalkyl C1-C6 alkyl, heterocyclyl or heterocyclyl C1-C6 alkyl, aryl or aryl C1-C6 alkyl, heteroaryl or heteroaryl C1-C6 alkyl or, taken together with the nitrogen atom to which they are bonded, either Ra and Rb as well as Rc and Rd may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof for use as a medicament.
